ApoE isoform-specific regulation of regeneration in the peripheral nervous system by Comley, L.H. et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ApoE isoform-specific regulation of regeneration in the
peripheral nervous system
Citation for published version:
Comley, LH, Fuller, HR, Wishart, T, Mutsaers, CA, Thomson, D, Wright, AK, Ribchester, R, Morris, GE,
Parson, S, Horsburgh, K & Gillingwater, T 2011, 'ApoE isoform-specific regulation of regeneration in the
peripheral nervous system' Human Molecular Genetics, vol. 20, no. 12, pp. 2406-2421. DOI:
10.1093/hmg/ddr147
Digital Object Identifier (DOI):
10.1093/hmg/ddr147
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Human Molecular Genetics
Publisher Rights Statement:
Open Oxford
© The Author 2011. Published by Oxford University Press. All rights reserved
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
ApoE isoform-specific regulation of regeneration
in the peripheral nervous system
Laura H. Comley1,2,{, Heidi R. Fuller4,5,{, Thomas M. Wishart1,2, Chantal A. Mutsaers1,2,
Derek Thomson1,2, Ann K. Wright1,2, Richard R. Ribchester1,2, Glenn E. Morris4,5,
Simon H. Parson1,2, Karen Horsburgh3 and Thomas H. Gillingwater1,2,∗
1Euan MacDonald Centre for Motor Neurone Disease Research, 2Centre for Integrative Physiology and 3Centre for
Cognitive and Neural Systems, University of Edinburgh, Edinburgh EH8 9XD, UK, 4Wolfson Centre for Inherited
Neuromuscular Disease, RJAH Orthopaedic Hospital and 5Institute for Science and Technology in Medicine, Keele
University, Oswestry SY10 7AG, UK
Received March 2, 2011; Revised and Accepted March 30, 2011
Apolipoprotein E (apoE) is a 34 kDa glycoprotein with three distinct isoforms in the human population
(apoE2, apoE3 and apoE4) known to play a major role in differentially influencing risk to, as well as outcome
from, disease and injury in the central nervous system. In general, the apoE4 allele is associated with poorer
outcomes after disease or injury, whereas apoE3 is associated with better responses. The extent to which
different apoE isoforms influence degenerative and regenerative events in the peripheral nervous system
(PNS) is still to be established, and the mechanisms through which apoE exerts its isoform-specific effects
remain unclear. Here, we have investigated isoform-specific effects of human apoE on the mouse PNS.
Experiments in mice ubiquitously expressing human apoE3 or human apoE4 on a null mouse apoE back-
ground revealed that apoE4 expression significantly disrupted peripheral nerve regeneration and subsequent
neuromuscular junction re-innervation following nerve injury compared with apoE3, with no observable
effects on normal development, maturation or Wallerian degeneration. Proteomic isobaric tag for relative
and absolute quantitation (iTRAQ) screens comparing healthy and regenerating peripheral nerves from
mice expressing apoE3 or apoE4 revealed significant differences in networks of proteins regulating cellular
outgrowth and regeneration (myosin/actin proteins), as well as differences in expression levels of proteins
involved in regulating the blood–nerve barrier (including orosomucoid 1). Taken together, these findings
have identified isoform-specific roles for apoE in determining the protein composition of peripheral nerve
as well as regulating nerve regeneration pathways in vivo.
INTRODUCTION
Genetic factors which influence the incidence and severity of
neurological conditions are the subject of intensive research,
as they offer the possibility of better prognostic/diagnostic
tools as well as the prospect of identifying novel therapeutic
approaches. One genetic factor that is a well-known modifier
of disease onset and progression in the central nervous
system (CNS) is apolipoprotein E (apoE). ApoE is a 34 kDa
glycoprotein and is a major determinant of lipid transport
and metabolism. There are three distinct isoforms present in
humans: apoE2, apoE3 and apoE4. Of these, apoE4, which
is present in one-third of the population, is most commonly
associated with an increased risk of neurodegeneration in the
CNS (1,2). It is well established that apoE4 is a major risk
factor for Alzheimer’s disease (3–5) as well as several other
neurodegenerative conditions, including Parkinson’s disease
(6,7). Similarly, apoE4 is associated with a poor outcome
after traumatic brain injury, stroke and intracranial haemor-
rhage (8–12). Conversely, apoE3 has been shown to attenuate
CNS degeneration in conditions such as Wilson’s disease (13).
Although the influence of apoE genotype on CNS injury and
disease is well established, there is only a partial understand-
ing of any potential influence of apoE genotype on the
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peripheral nervous system (PNS) (14,15). This lack of knowl-
edge is rather surprising given that ApoE is expressed through-
out the PNS, including at the neuromuscular junction (NMJ)
(16,17), where expression levels dramatically increase in
response to nerve crush injury and exposure to harmful
environmental stimuli (18–20). Although an association
between apoE genotype and disease outcome has been demon-
strated for human patients with diabetic neuropathies (21,22),
the influence of apoE genotype on other human PNS dis-
orders—such as motor neuron disease—remains controversial
(23–32). Previous studies using genetically modified animals
to examine degeneration and regeneration in the PNS have
only investigated the effects of complete loss of apoE
expression (33,34), rather than the more biologically relevant
question of the influence of the apoE isoform.
Similarly, the underlying mechanisms through which differ-
ent apoE isoforms differentially affect the nervous system
remain unclear. New experimental approaches to explore the
mechanisms through which apoE influences the nervous
system are therefore required. The PNS offers an ideal,
experimentally accessible model system with which to study
the influence of apoE isoforms on a variety of in vivo pro-
cesses, including development, maturation, degeneration and
regeneration.
Here, we have used mouse models to compare the conse-
quences of human apoE3 and human apoE4 expression on
the form, function and molecular composition of the healthy
and degenerating PNS.
RESULTS
ApoE4 significantly delays nerve regeneration and
neuromuscular re-innervation following peripheral
nerve injury
Previous studies reported that complete loss of apoE had no
effect on nerve regeneration in the mouse PNS, following
nerve injury (33,34). However, the more biologically relevant
question of whether apoE3 or apoE4 can influence regener-
ation and neuromuscular re-innervation in the PNS was not
addressed. We therefore set out to examine the influence of
apoE genotype on regeneration in the PNS, using established
transgenic mice expressing human apoE3 or apoE4 on a null
mouse apoE background [apoE2/2;apoE3 and apoE2/2;
apoE4; see Materials and Methods and reference (35)].
ApoE2 mice were not used for this study, as they express
apoE at levels much higher than the apoE3 or apoE4 mice
(35); thus, it would have been impossible to determine
whether any effects observed were due to the genotype or
were simply occurring due to differences in expression
levels of apoE.
First, it was important to determine that apoE was expressed
at similar levels in the transgenic lines used, to ensure that any
differences observed were not due to a relative over-
expression of one isoform. We therefore examined apoE
expression levels in tibial nerves from apoE2/2;apoE3 and
apoE2/2;apoE4 mice expressing human apoE3 or apoE4 and
compared them with samples from wild-type (WT) mice and
apoE2/2 mice. As expected (9,35), apoE protein was
undetectable in peripheral nerves from WT mice and
apoE2/2 mice [endogenous apoE is only expressed at low
levels in the nervous system (9)]. However, apoE protein
was generated from the human apoE3 and apoE4 transgenes
in the peripheral nerve and was expressed at near-identical
levels in nerves from apoE3 and apoE4 mice (Fig. 1).
We then quantified axon regeneration in the tibial nerve of
apoE3 and apoE4 mice at 2 and 3 weeks following sciatic
nerve injury (Fig. 2). At 1 week post-injury (the period
when regeneration is beginning following the completion of
Wallerian degeneration in vivo: see what follows), there was
no difference in the numbers of axons in the sciatic nerve
from apoE3 and apoE4 mice. However, at 2 weeks post-injury,
apoE4 mice showed a significant reduction in the numbers of
regenerating axons in the sciatic nerve compared with apoE3
mice (63% regeneration compared with apoE3 mice; P ,
0.05; Fig. 2). This significant delay in regeneration was also
present in apoE4 mice 3 weeks after injury, where regener-
ation was virtually complete in apoE3 mice, but had only
reached 70% of apoE3 levels in apoE4 mice (P, 0.05;
Fig. 2).
To confirm that the delay in axon regeneration observed in
apoE4 mice subsequently resulted in impaired functional
re-innervation of peripheral targets by regenerating axons,
we quantified re-innervation of NMJs in the lumbrical
muscles (innervated by the tibial nerve) of apoE3 and apoE4
mice after tibial nerve injury. At 2 weeks following nerve
injury, lumbrical muscles in apoE4 mice had a significantly
reduced number of re-innervated endplates compared with
apoE3 mice (Fig. 3). We used fluorescent quantitative
western blotting to establish that the delay in axon regener-
ation and neuromuscular re-innervation observed in apoE4
Figure 1. ApoE3 and apoE4 isoforms are expressed at equivalent levels in
apoE3 and apoE4 transgenic mice. (A) Representative fluorescent western
blot for apoE protein in the uninjured sciatic nerve of WT, apoE2/2 (2/2),
apoE3 (E3) and apoE4 (E4)mice. (B) Bar chart (mean+SEM) showing quanti-
fication of apoE expression levels normalized to beta III tubulin loading control,
confirming no difference in expression levels between apoE3 and apoE4 (P .
0.05, apoE3 versus apoE4; one-way ANOVA with Tukey’s post hoc test; n ¼
3 for each genotype; ns, not significant).
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mice was not occurring due to differing expression levels of
human apoE transgenes after nerve injury. Expression levels
of apoE protein were identical in tibial nerves from apoE3
and apoE4 mice 2 weeks after nerve crush (Supplementary
Material, Fig. S1). Taken together, these data show that
apoE4 selectively delays nerve regeneration in the PNS.
ApoE genotype has no effect on normal form or function
of the mouse PNS
To determine that the effects on regeneration were not occur-
ring as an indirect result of pre-existing changes in the form or
function of the uninjured PNS induced by different apoE gen-
otypes, we next examined neuronal morphology and function
in uninjured nerves and muscles from apoE3 and apoE4 mice
and compared them with apoE2/2 and WT mice. No qualitat-
ive or quantitative differences were observed in the mor-
phology of the sciatic nerve or NMJs between mice of
different genotypes (Fig. 4). Similarly, electrophysiological
measurements from apoE4 mice suggested normal neuromus-
cular synaptic function in mice expressing a human apoE
transgene: there were no effects on the rise time, amplitude
or decay time of evoked endplate potentials (EPPs) and no dis-
cernible effect on miniature endplate potential (mEPP) fre-
quency, amplitude or time course (Fig. 4). Developmental
synaptic plasticity in the PNS was also unaltered in the pres-
ence of human apoE protein (Supplementary Material,
Fig. S2). Thus, expression of either human apoE3 or apoE4
had no detrimental effect on the form, function or develop-
ment of the uninjured mouse PNS.
ApoE genotype does not significantly delay Wallerian
degeneration of axons or synapses following peripheral
nerve injury
As apoE4 has been shown to modulate neurodegenerative
events in the CNS (9,36–38), we next asked whether the pres-
ence of apoE3 or apoE4 influenced the rate of re-innervation
Figure 2. ApoE4 significantly impairs nerve regeneration following sciatic nerve injury. (A) Representative electron micrographs of cross-sections from adult
sciatic nerves in apoE3 (E3) and apoE4 (E4) mice,1, 2 and 3 weeks after sciatic nerve crush. Scale bar ¼ 10 mm. (B) Scatter plot (mean+SEM) showing time
course of axonal regeneration in apoE3 and apoE4 sciatic nerves following sciatic nerve crush. At both 2 and 3 weeks post-crush, apoE4 significantly delays
regeneration (63 and 70% that of the levels of apoE3 axon regeneration at the same time points, respectively. 1 week, P . 0.05; t-test, two-tailed; apoE3, n ¼ 3;
apoE4, n ¼ 2. 2 weeks, P , 0.05; t-test, two-tailed; apoE3, n ¼ 6; apoE4, n ¼ 6. 3 weeks, P , 0.05; t-test, two-tailed; apoE3, n ¼ 11; apoE4, n ¼ 11).
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by affecting the prior process of degeneration in the PNS,
which is an essential pre-requisite for re-innervation. The
extent of Wallerian degeneration occurring at NMJs in lumb-
rical muscles 24 h after tibial nerve cut injury was identical in
apoE3 and apoE4 (Fig. 5A), similar to previous descriptions of
Wallerian degeneration in WT mice (39,40). Likewise, Wal-
lerian degeneration of axons in the sciatic nerve 1 week
after nerve crush occurred identically in apoE3 and apoE4
mice (Fig. 5B and C). Thus, apoE genotype did not signifi-
cantly delay Wallerian degeneration in the PNS, confirming
that the impaired regeneration phenotype observed in apoE4
mice was occurring solely as a result of apoE4 directly mod-
ulating regeneration pathways in the peripheral nerve.
ApoE genotype modifies expression levels of proteins
associated with cellular outgrowth and blood–nerve
barrier integrity in peripheral nerve
Given our finding that apoE genotype selectively modifies
nerve regeneration in the PNS, we next set out to identify
potential molecular mechanisms regulating apoE-specific
responses in the PNS in vivo. First, we used an iTRAQ (isoba-
ric tag for relative and absolute quantitation) proteomic
approach to compare protein expression levels in uninjured
tibial nerve preparations from apoE3 and apoE4 mice (n ¼ 9
mice per genotype, pooled into three independent samples
per genotype). Importantly, it should be noted that these
initial proteomic experiments were designed to detect
changes in the peripheral nerve proteome occurring solely as
a result of the presence of different isoforms of apoE, in the
absence of any other external stimuli (e.g. nerve degeneration
or regeneration). It should also be noted that our peripheral
nerve preparations contained all of the cell types and tissues
present in the peripheral nerve (e.g. not just axons of
neurons but also glial cells, capillaries, extracellular matrix,
etc.). These non-neuronal cells and tissues are important to
consider in such experiments, as they play a key role in
establishing a local microenvironment conducive to nerve
regeneration.
Only proteins identified with .95% total ion score confi-
dence intervals and by two or more unique peptides were
accepted as being robust and reliable enough for inclusion in
our analysis. Using this approach, 62 proteins showed
increased expression levels .20% in uninjured peripheral
nerves from apoE4 mice compared with apoE3 peripheral
nerves (Table 1), and 40 proteins had decreased expression
levels .20% in apoE4 peripheral nerves (Table 2). Note
that neither of the protein products from the apoE3 or apoE4
transgenes was present on the tables of changed proteins as
they are both human proteins and the analysis software was
set to identify only mouse proteins. It should also be noted
that, although the protein identifications were statistically sig-
nificant (i.e. detected with two or more peptides and total ion
scores of .95% confidence intervals), it was not always poss-
ible to distinguish between closely related protein isoforms
(e.g. of myosin) unless proteotypic peptides (i.e. peptides
that were entirely unique in sequence to that isoform) were
detected. Thus, it is possible that specific isoforms of a
protein (e.g. myosin) identified in this study may actually rep-
resent another closely related isoform in addition to, or in
place of, the isoform actually listed.
Systems level analysis of protein expression changes using
Ingenuity Pathway Analysis (IPA) software (see Materials and
Methods) revealed potential changes in protein interaction net-
works associated with the regulation of tissue and cell mor-
phology (based around interactions of myosin and actin
proteins; Supplementary Material, Fig. S3A) and haematologi-
cal regulation (including integrity of the blood–brain barrier
(BBB)/blood–nerve barrier (BNB); Supplementary Material,
Fig. S3B) in apoE4 mice. Taken together, these data show
that expression of different apoE isoforms leads to significant
modifications in the peripheral nerve proteome, even in the
absence of injury or disease.
Given that these initial proteomic experiments were
designed to detect changes in the peripheral nerve proteome
occurring solely as a result of the presence of different iso-
forms of apoE, it was interesting to note numerous changes
in expression levels of several myosin proteins that contribute
to myosin/actin interaction networks in apoE4 mice, in the
absence of any changes in corresponding actin proteins.
Myosin proteins contributing to myosin/actin networks are
Figure 3. ApoE4 significantly impairs neuromuscular re-innervation following
nerve crush injury in the mouse PNS. (A) Representative confocal micro-
graphs showing immunohistochemically labelled NMJs from apoE3 and
apoE4 lumbrical muscles 2 weeks after a tibial nerve crush. Pre-synaptic
axons and motor nerve terminals are shown in green and post-synaptic acetyl-
choline receptors labelled with a-BTX are shown in red. Note how the apoE3
endplates have all been re-innervated, whereas some apoE4 endplates are still
vacant and awaiting re-innervation (white arrows) at the same time-point.
Scale bar ¼ 30 mm. (B) Bar chart (mean+SEM) showing levels of neuro-
muscular re-innervation in lumbrical muscles 2 weeks after a tibial nerve
crush. Re-innervation was significantly impaired in apoE4 mice compared
with apoE3 mice (P, 0.001; Mann–Whitney test, two-tailed; apoE3, n ¼ 5
mice; apoE4, n ¼ 5 mice).
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responsible for delivering the actin scaffold to relevant parts of
the cell during periods of cell growth or reorganization, but
concomitant changes in actin levels would be essential for
the pathway to modify cell morphology (41–43). These find-
ings were therefore consistent with our morphological data
from the uninjured PNS, showing that apoE4 expression did
not affect the normal form or function of the PNS, as might
have been expected had actin protein levels also been
altered. However, the changes we observed in myosin proteins
in uninjured apoE4 nerves may represent a ‘priming’ response
that does not result in any overt phenotype, but which could
conceivably influence actin dynamics in response to stimuli
inducing cell remodelling (e.g. peripheral nerve regeneration
following nerve injury).
To test whether modifications in both actin and myosin
components of myosin/actin interaction networks were conse-
quently modified in regenerating peripheral nerves from
apoE4 mice, we repeated our iTRAQ proteomic experiments
using regenerating tibial nerves from apoE3 and apoE4 mice
3 weeks after nerve crush injury (n ¼ 9 mice per genotype,
pooled into three independent samples per genotype). As in
our experiments on unlesioned nerves, there were large
numbers of proteins with altered expression in regenerating
nerves from apoE4 mice compared with apoE3 mice
(Tables 3 and 4). Many of these proteins were similar to
those changed in unlesioned nerves, including proteins
involved in haematological regulation (e.g. haptoglobin and
orosomucoid 1). However, even more marked changes were
observed in expression levels of both myosin and actin pro-
teins (Table 4). These findings were supported by systems
level analysis: 55% of total proteins in one single myosin/
actin interaction network had altered expression in uninjured
nerves (Supplementary Material, Fig. S3A), whereas 83 and
86% of proteins contributing to two myosin/actin networks
had modified expression levels in regenerating apoE4 nerves
(Supplementary Material, Fig. S4A and B). Given the impor-
tance of myosin/actin pathways in driving cellular reorganiz-
ation required for processes such as regeneration (41–43),
the widespread reductions in expression of key proteins contri-
buting to these networks in the apoE4 peripheral nerve are
likely to play a significant role in reducing their regenerative
capacity.
Figure 4. Expression of human apoE has no effect on normal axonal or neuromuscular form or function. (A) Representative electron micrographs of cross-
sections from adult sciatic nerves in WT, apoE2/2 (2/2), apoE3 (E3) and apoE4 (E4) mice. All genotypes had healthy myelinated axon profiles. Scale
bar ¼ 10 mm. (B) Bar chart (mean+SEM) showing no significant difference in the number of myelinated axons in WT, apoE2/2, apoE3 and apoE4 mice
(P. 0.05; one-way ANOVA with Tukey’s post hoc test; WT, n ¼ 3; apoE2/2, n ¼ 5; apoE3, n ¼ 5; apoE4, n ¼ 3). (C) Representative confocal micrographs
showing immunohistochemically labelled NMJs in LAL muscles showing mono-innervated, fully occupied endplates (i.e. ‘normal’ morphology) in WT,
apoE2/2 (2/2), apoE3 (E3) and apoE4 (E4) mice. More than 98% of NMJs in all muscles examined, regardless of genotype, showed these morphological
characteristics. Pre-synaptic axons and motor nerve terminals are shown in green and post-synaptic acetylcholine receptors labelled with a-BTX are shown
in red. Scale bar ¼ 30 mm. (D) Bar chart (mean+SEM) showing no significant difference in the percentage of fully occupied, mono-innervated WT,
apoE2/2, apoE3 and apoE4 mice (P . 0.05; Kruskal–Wallis test with Dunn’s post hoc test; WT, n ¼ 8; apoE2/2, n ¼ 7; apoE3, n ¼ 7; apoE4, n ¼ 7). (E)
apoE2/2 and apoE4 mice both showed robust EPPs in the FDB muscle in response to tibial nerve stimulation. (F) There was no significant difference in
the amplitude of EPPs between apoE2/2 and apoE4 mice. (P . 0.05; t-test, two-tailed; apoE2/2, n ¼ 73 fibres, n ¼ 3 mice; apoE4, n ¼ 75 fibres, n ¼ 3
mice). (G) Muscles from both genotypes showed spontaneous mEPPs at an equivalent rate (P . 0.05; t-test, two-tailed; apoE2/2, n ¼ 78 fibres, n ¼ 3 mice;
apoE4, n ¼ 80 fibres, n ¼ 3 mice). (H) There was no significant difference in quantal content between apoE2/2 and apoE4 mice (P . 0.05; t-test, two-tailed;
apoE2/2, n ¼ 48 fibres, n ¼ 3 mice; apoE4, n ¼ 32 fibres, n ¼ 3 mice). ns, not significant.
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DISCUSSION
In this study, we have demonstrated apoE genotype-dependent
regulation of nerve regeneration in the PNS and used this
finding to examine molecular mechanisms underlying
deficient neurite outgrowth in peripheral nerves expressing
apoE4. We showed that the presence of apoE4 selectively
delays nerve regeneration and neuromuscular re-innervation
compared with mice expressing apoE3, in the absence of
any significant effects on the form, function, degeneration or
developmental plasticity of the PNS. Comparative iTRAQ
proteomics revealed concomitant significant changes to the
proteome of the peripheral nerve in apoE4 mice, compared
with that in apoE3 mice, with modified expression levels of
proteins that contribute to the regulation of cellular outgrowth
and regeneration (based around myosin/actin interactions) and
haematological regulation (e.g. of the BNB).
The most notable phenotypic observation in the current
study was a significant and selective impairment of nerve
regeneration and neuromuscular re-innervation in the PNS of
apoE4 mice following peripheral nerve injury. These data
from the PNS are in agreement with previous in vitro
studies of neurons from the CNS, showing that neurite out-
growth can be inhibited by apoE4 (44–46) and that intrinsic
neuronal repair mechanisms are compromised in the presence
of apoE4 in response to CNS injury (47). Our finding that
apoE4 influences regenerative processes in the PNS also pro-
vides a possible explanation for several previous human cohort
studies reporting associations between apoE genotype and pro-
gressive diseases of the PNS, including diabetic and
HIV-associated neuropathies (21,22,48) and motor neuron
disease. For the latter, there have been a number of human
cohort studies investigating a possible relationship between
the apoE4 allele and motor neuron disease, with conflicting
results (23–29,31,32). Motor neuron regeneration has been
shown to play a significant role in amyotrophic lateral scler-
osis (ALS): as some motor neurons degenerate, leaving dener-
vated muscle fibres, others sprout in an attempt to re-innervate
vacant motor endplates and prolong muscle function (49). The
findings reported here suggest that possession of the apoE4
allele could impact on disease progression in conditions such
as ALS, as neurons in patients with apoE4 may have a
reduced capacity for sprouting and re-innervation. Thus,
knowledge of the apoE genotype status of individual human
patients with peripheral nerve trauma or disease may
provide valuable insights into the likelihood of success of
regenerative events in the PNS and hence help to inform the
likely rate of recovery or decline (15).
Our proteomic experiments revealed a significant influence
of apoE genotype on the peripheral nerve proteome, both in
uninjured nerves and in regenerating nerves. The limitations
of this approach mean that we could only detect changes in
global expression levels rather than gaining insights into
more dynamic cellular processes (e.g. changes in subcellular
localization and/or modified binding activity of specific or
groups of proteins). However, our experiments did reveal
changes in expression levels of a range of different myosin
and actin proteins. Importantly, as we identified modified
expression levels for a large number of myosin isoforms in
uninjured nerves from apoE4 mice, it is possible to conclude
that apoE4-mediated disruptions in myosin/actin networks
were occurring as a direct consequence of the apoE genotype,
and not simply as a result of impaired nerve regeneration in
apoE4 mice. It has long been known that dynamic regulation
of the actin cytoskeleton is a key regulator of cell morphology
Figure 5. Wallerian degeneration of NMJs and axons following peripheral
nerve crush injury occurs identically in apoE3 and apoE4 mice. (A) Bar
chart (mean+SEM) showing no significant difference between the percen-
tage of denervated endplates observed in apoE3 and apoE4 lumbrical
muscles 24 h after tibial nerve crush (P . 0.05; Mann–Whitney test, two-
tailed; apoE3, n ¼ 5; apoE4, n ¼ 3 mice). (B) Representative electron micro-
graphs of cross-sections from adult sciatic nerves in apoE3 (E3) and apoE4
(E4) mice 1 week after sciatic nerve crush. Scale bar ¼ 10 mm. (C) Bar
chart (mean+SEM) showing reduced numbers of myelinated axons in
apoE3 and apoE4 sciatic nerves 1 week after nerve crush injury (0 and
1 weeks: P . 0.05; one-way ANOVA with Tukey’s post hoc test; 0 week:
apoE3, n ¼ 5; apoE4, n ¼ 3. 1 week: apoE3, n ¼ 3 mice; apoE4, n ¼ 2).
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Table 1. iTRAQ identification of proteins with .20% increased expression and peptide count .1 in the unlesioned sciatic nerve from ApoE4 mice compared
with ApoE3 mice
Protein name Accession
number
Protein
MW
Protein
PI
Peptide
count
Total ion score,
CI percentage
Best ion
score
Average ratio
(E4/E3)
Standard
deviation
(E4/E3)
Haptoglobin precursor 8850219 42455.7 5.9 7 100.00 67.94 3.39 1.42
Orosomucoid 1 15215270 26393.8 5.4 5 100.00 58.65 2.05 0.53
Myomesin 2 170763465 179757.5 5.6 11 100.00 72.44 1.80 0.35
PK-120 precursor 2739028 112522.4 6.1 2 100.00 52.16 1.67 0.03
Myosin, heavy polypeptide 4, skeletal
muscle
67189167 254149.5 5.6 85 100.00 127.38 1.67 0.44
Haemopexin precursor 160358829 55053.3 7.9 15 100.00 95.47 1.63 0.42
Muscle glycogen phosphorylase 6755256 104509.5 6.7 18 100.00 93.56 1.63 0.33
Myosin-binding protein C, fast type 81910387 143381.3 6.0 10 100.00 100.37 1.62 0.49
ATPase, Ca++ transporting, ubiquitous 74215005 116671.4 5.5 2 100.00 48.16 1.61 0.09
Major urinary protein 295910 22495.3 4.9 3 100.00 85.86 1.59 0.23
Major urinary protein 13276755 22609.4 5.0 3 100.00 85.86 1.58 0.21
MUP 755765 17535.8 4.9 2 100.00 62.95 1.53 0.12
Myh7 protein 187956918 252607.1 5.6 20 100.00 91.72 1.51 0.56
Alpha cardiac myosin heavy chain 191618 253883.5 5.6 18 100.00 91.72 1.48 0.58
Muscle creatine kinase 6671762 48101.2 6.6 14 100.00 101.99 1.45 0.34
S100 calcium binding protein A9
(calgranulin B)
6677837 14907.5 6.6 2 100.00 69.01 1.45 0.09
Solute carrier family 4 (anion exchanger),
member 1
74138529 108215.2 5.4 2 100.00 50.97 1.45 0.01
Fibrinogen, gamma polypeptide 74143561 55480.4 5.4 6 100.00 84.66 1.43 0.09
Titin 123232572 3312853.3 6.2 2 100.00 37.84 1.43 0.05
Fibrinogen beta chain precursor 33859809 60169.0 6.7 12 100.00 78.56 1.41 0.29
Myosin, heavy polypeptide 8, skeletal
muscle, perinatal
71143152 253848.8 5.7 46 100.00 106.43 1.40 0.58
Parvalbumin 31980767 14372.8 5.0 5 100.00 88.79 1.40 0.19
Myosin, heavy polypeptide 8, skeletal
muscle, perinatal
187956525 253835.8 5.7 46 100.00 106.43 1.39 0.57
Haemoglobin, beta adult major chain 31982300 17513.4 7.1 13 100.00 107.43 1.36 0.22
Clusterin precursor 214010170 56451.5 5.5 4 100.00 82.73 1.36 0.47
mCG18455 148678485 256334.6 5.5 22 100.00 84.80 1.36 0.71
Troponin T 2340048 34082.0 9.4 4 100.00 78.26 1.35 0.16
Haemoglobin alpha, adult chain 2 145301549 16878.0 8.0 9 100.00 101.60 1.35 0.25
ATPase, Ca++ transporting, cardiac
muscle, fast twitch 1
148685412 116243.4 5.3 12 100.00 114.25 1.35 0.24
Actinin alpha 3 7304855 110400.7 5.3 34 100.00 112.37 1.34 0.46
Phosphofructokinase, muscle 13529638 92278.8 8.2 8 100.00 67.00 1.34 0.11
Collagen, type VI, alpha 1 precursor 6753484 117555.5 5.2 7 100.00 91.16 1.33 0.17
Glutamine synthetase 31982332 45842.4 6.6 2 100.00 67.62 1.33 0.04
Myomesin 1 isoform 2 145279198 194032.5 6.0 7 100.00 81.84 1.33 0.13
Sarcalumenin, isoform CRA_a 148664814 59761.7 6.2 4 100.00 60.15 1.31 0.25
ATPase, Ca++ transporting, slow twitch 2
isoform a
158635979 124907.5 5.2 5 100.00 68.51 1.31 0.33
Histone cluster 1, H1c 9845257 29755.8 11.0 2 100.00 75.68 1.30 0.17
mCG2006, isoform CRA_a 148680420 187536.8 6.3 2 100.00 60.73 1.30 0.12
Glycogen phosphorylase, liver form 20178036 107417.7 6.6 5 100.00 58.28 1.29 0.20
Phosphoglycerate mutase 2 9256624 31972.9 8.7 8 100.00 89.17 1.29 0.17
Enolase 3, beta muscle, isoform CRA_a 148680653 54402.9 6.8 15 100.00 112.63 1.28 0.28
Sorbitol dehydrogenase 22128627 42431.2 6.6 2 100.00 54.45 1.28 0.23
RIKEN cDNA 1810020D17, isoform
CRA_c
148684357 17880.5 7.8 2 100.00 44.25 1.27 0.04
Unnamed protein product 26345578 19080.7 10.5 3 100.00 67.62 1.26 0.17
Cullin 1 7549752 100115.9 8.2 2 100.00 53.35 1.26 0.23
Hormone-sensitive lipase (Mus musculus
domesticus)
677885 87018.7 6.5 2 100.00 60.78 1.25 0.03
Epoxide hydrolase 1 6753762 57724.5 8.4 2 100.00 53.93 1.24 0.10
Collagen, type VI, alpha 2 precursor 22203747 118822.8 6.0 11 100.00 63.77 1.24 0.16
Aldolase A, fructose-bisphosphate 42490830 43401.8 8.5 11 100.00 91.23 1.23 0.10
Preprocomplement component C3 309122 205041.7 6.4 6 100.00 56.08 1.23 0.18
Phosphatidylinositol-4-phosphate 5-kinase
type II beta
17223780 50243.1 6.4 2 100.00 52.71 1.23 0.27
Fast skeletal myosin alkali light chain 1
isoform 1f
29789016 23699.5 5.0 14 100.00 97.84 1.22 0.18
Adenylate kinase 1 10946936 26311.9 5.7 5 100.00 77.64 1.22 0.24
Continued
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and outgrowth in many cell types, including neurons (41,50).
More recently, however, it has become clear that regulated
interactions between myosin and actin proteins in neurons
are required for successful outgrowth and nerve regeneration.
For example, many members of the myosin family of proteins
are present in neuronal axons and synaptic terminals
(42,51,52). Myosin proteins directly influence neurite out-
growth and retraction in vitro and in vivo (42,43), regulate
the localization and distribution of cytoskeletal proteins in
neurons (53–55) and also contribute to axonal pathfinding
and neuronal development (56,57). In addition, similar to
apoE, myosin 5A is synthesized locally following nerve
injury (58), suggesting a role in delivering the required actin
cytoskeleton for nerve regeneration in vivo. It is also likely
that modified levels of myosin and actin proteins in non-
neuronal cells would change the dynamics of the local
microenvironment required for successful peripheral nerve
regeneration. Thus, the widespread modification in expression
levels of both myosin and actin proteins in apoE4 peripheral
nerves may contribute to the impaired nerve regeneration
observed in apoE4 mice. These initial insights suggest that
more detailed biochemical investigations of the role of actin
and myosin proteins in regulating apoE genotype-dependent
regeneration of the peripheral nerve are now warranted.
Our proteomic experiments also revealed a significant influ-
ence of apoE genotype on the expression levels of proteins
associated with haematological regulation, several of which
are important for the integrity of the BBB/BNB. This
finding was particularly interesting given that apoE has pre-
viously been shown to be essential for BBB and BNB integ-
rity, although only in studies that examined the effect of
complete loss of apoE, using apoE2/2 mice (59,60). The
data showing changes in levels of proteins including orosomu-
coid 1, fibrinogen, haptoglobin and haemopexin in uninjured
and regenerating apoE4 nerves therefore provide insights
into the potential molecular mechanisms through which
apoE genotype can modulate haematological features associ-
ated with the nervous system. Orosomucoid 1, in particular,
is a protein that modulates the permeability of the BBB
(61), and was up-regulated in uninjured and regenerating
nerves from apoE4 mice. Similarly, fibrinogen (up-regulated
in apoE4 nerves) is a mediator of neuronal damage following
disruption to the BBB (62). Although it is not possible at
present to directly link the changes observed in
haematological-related proteins to the deficient regeneration
observed in apoE4 mice, the finding that disruption of the
BNB impairs nerve regeneration (63) suggests that it may at
least contribute to this response. Further work is now required
to determine whether the specific proteins identified in the
current study are also modified in the CNS, and whether
they directly impair haematological regulation and BBB integ-
rity in an apoE-genotype-dependent manner.
In summary, we have shown that apoE genotype is a signifi-
cant determinant of the success of nerve regeneration in the
PNS in vivo, with apoE4 selectively impairing regeneration
of axons and re-innervation of NMJs following nerve injury
in mice. Insights from comparative proteomic experiments
demonstrated concomitant apoE-isoform-dependent changes
in the peripheral nerve proteome, several of which are likely
to have significant consequences for the form and function
of the PNS.
MATERIALS AND METHODS
Mice
All animal experiments were approved by a University of
Edinburgh internal ethics committee and were performed
under license by the UK Home Office (project licence
number 60/3891). Young adult mice expressing human
apoE4 on a mouse apoE2/2;C57BL/6J background were com-
pared with littermate apoE2/2 mice or apoE3 mice on an
apoE2/2;C57BL/6J background. For experiments examining
the influence of loss of apoE, apoE2/2 mice were compared
with age-matched C57Bl/6J (WT) mice. Detailed information
on the breeding and characteristics of apoE transgenic mice
has previously been reported (35). Briefly, human apoE4 and
apoE3 transgenic mice were generated on an apoE-deficient
C57BL/6J background, utilizing human apoE4 or apoE3 trans-
genic constructs (35). Mice were supplied via a collaboration
with Dr Allen Roses (Duke University) and breeding colonies
established at the University of Edinburgh. ApoE4 and apoE3
Table 1. Continued
Protein name Accession
number
Protein
MW
Protein
PI
Peptide
count
Total ion score,
CI percentage
Best ion
score
Average ratio
(E4/E3)
Standard
deviation
(E4/E3)
Fibrinogen, alpha polypeptide, isoform
CRA_b
148683477 68946.6 7.0 6 100.00 64.58 1.21 0.23
Lactate dehydrogenase A isoform 1 6754524 40772.0 7.6 13 100.00 74.65 1.21 0.13
Chain B, X-ray structure of the nucleosome
core particle
27573730 12958.6 11.4 4 100.00 53.05 1.21 0.14
2′,3′-cyclic nucleotide 3′
phosphodiesterase isoform 2
226423907 53755.9 9.1 24 100.00 122.44 1.21 0.17
ATPase, H+ transporting, lysosomal V1
subunit H
14318722 60928.4 6.2 2 100.00 61.01 1.20 0.02
Chaperonin 460317 64225.7 8.2 2 100.00 98.95 1.20 0.15
Tyrosyl-tRNA synthetase 165377181 68152.2 6.6 2 100.00 40.36 1.20 0.14
Glyoxalase 1 19354350 23702.3 5.2 2 100.00 47.51 1.20 0.33
Xanthine dehydrogenase 187954915 159925.8 7.6 3 100.00 51.62 1.20 0.06
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transgenic mice were backcrossed with genetically homo-
geneous apoE-deficient mice (Charles River) for more than
10 generations (crossed to C57Bl/6J mice to reduce any
genetic interference of the DBA/2 J background strain), result-
ing in mice heterozygous for the human apoE transgenes E4 or
E3 on a homozygous mouse apoE background. The presence
of mouse apoE genes was determined by PCR analysis of
extracted DNA as described previously (35). Importantly,
these mouse lines were selected for the current study, as
apoE3 and apoE4 transgenes are known to be expressed at
physiological levels, similar to those found in humans
(9,35,64). All animals were housed in standard conditions
and all procedures were carried out under licensed authority
from the UK Home Office.
Surgery
Mice were anaesthetized by inhalation of halothane (2% in 1:1
N2O/O2) before exposing the sciatic nerve in the thigh or the
tibial nerve above the heel. For nerve crush experiments, the
sciatic or tibial nerve was crushed between a pair of fine-point
forceps for 30 s. Nerves were checked to ensure a complete
Table 2. iTRAQ identification of proteins with .20% decreased expression and peptide count .1 in the unlesioned sciatic nerve from ApoE4 mice compared
with ApoE3 mice
Protein name Accession
number
Protein
MW
Protein
PI
Peptide
count
Total ion score, CI
percentage
Best ion
score
Average ratio
(E4/E3)
Standard
deviation
(E4/E3)
Myosin, light polypeptide 6B 26986555 25852.8 5.4 4 100.00 69.41 0.19 0.12
Myoglobin 21359820 20131.1 7.1 10 100.00 143.49 0.49 0.07
Myosin, light polypeptide 3, isoform CRA_a 148677054 27359.4 5.0 5 100.00 54.09 0.51 1.25
h1-calponin alpha 1069994 36759.9 8.8 4 100.00 68.12 0.54 0.03
Igh protein 62028521 56919.8 7.5 3 100.00 71.06 0.57 0.08
Ig H-C allotype gamma2b 223428 40724.8 7.2 2 100.00 90.21 0.61 0.03
h-caldesmon 17017241 43428.3 5.3 2 100.00 70.01 0.63 0.25
Light chain of the monoclonal antibody
MST2
1617395 27982.7 7.0 2 100.00 55.34 0.66 0.03
Skeletal muscle LIM protein 2880031 38678.1 8.8 2 100.00 78.07 0.67 0.02
Heat shock protein, alpha-crystallin-related,
B6
59958370 18132.5 5.6 3 100.00 54.71 0.68 0.09
Chain A, crystal structure of mouse
transthyretin
161172183 15211.9 5.8 3 100.00 94.87 0.69 0.08
Actinin alpha 2 157951643 112009.7 5.3 23 100.00 112.37 0.69 0.22
LIM domain binding 3 isoform b 84872213 76092.4 8.3 3 100.00 70.38 0.70 0.10
Filamin, alpha 125347376 305825.3 5.7 29 100.00 89.05 0.71 0.09
Fibromodulin precursor 10946680 44933.6 5.9 2 100.00 43.37 0.71 0.13
Milk fat globule-EGF factor 8 protein
isoform 2
113865977 50796.5 6.7 5 100.00 83.22 0.71 0.08
Transgelin 6755714 25201.2 8.9 8 100.00 88.00 0.71 0.04
Myosin 1945080 253502.8 5.4 17 100.00 83.10 0.72 0.15
PDZ and LIM domain protein 3 7948997 36807.6 8.1 3 100.00 68.49 0.72 0.17
Myosin regulatory light polypeptide 9 198278553 22033.0 4.9 6 100.00 74.98 0.72 0.04
Collagen alpha-1(XIV) chain 146345398 206682.6 5.0 8 100.00 93.04 0.74 0.05
Procollagen, type I, alpha 2 precursor 111120329 136953.2 9.3 8 100.00 77.32 0.75 0.17
Destrin, isoform CRA_b 148696488 28666.5 9.0 5 100.00 66.15 0.76 0.08
LIM domain containing preferred
translocation partner in lipoma isoform 1
225543157 71700.8 7.2 4 100.00 52.29 0.76 0.09
Actinin alpha 2 58476244 111806.5 5.3 20 100.00 112.37 0.76 0.27
Ig gamma-3 chain C region 121044 47963.7 6.7 3 100.00 46.58 0.76 0.03
Proteasome alpha 6 subunit 6755198 30608.7 6.3 3 100.00 75.58 0.77 0.21
Protein phosphatase 1 471976 42247.5 5.8 2 100.00 43.57 0.77 0.01
Chain A, crystal structure of the Ap-2 clathrin
adaptor alpha
5822376 29953.4 6.9 2 100.00 49.31 0.78 0.06
Gfap protein 72679718 51278.8 5.1 3 100.00 45.03 0.78 0.19
Albumin precursor 163310765 77836.5 5.8 36 100.00 121.79 0.78 0.12
Probable ATP-dependent RNA helicase
DDX5
2500527 74734.3 9.1 2 100.00 50.01 0.78 0.02
Adipsin precursor 7304867 29317.2 6.2 2 100.00 44.03 0.79 0.05
PDZ and LIM domain 5, isoform CRA_c 148680118 57492.2 8.2 3 100.00 82.11 0.79 0.09
Heterogeneous nuclear ribonucleoprotein L 183980004 68765.9 7.3 3 100.00 77.22 0.79 0.03
Fibulin 2 13529413 134192.5 4.6 2 100.00 43.20 0.79 0.02
EF hand domain containing 2 31981086 28253.9 5.0 2 100.00 43.24 0.79 0.17
Serpin peptidase inhibitor, clade C, member 1
precursor
18252782 57428.0 6.1 3 100.00 49.87 0.79 0.12
mKIAA0777 protein 28972395 139280.4 8.4 4 100.00 88.73 0.79 0.23
Carboxylesterase 192854 65222.7 5.0 8 100.00 84.01 0.80 0.11
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crush had been performed before suturing the skin and allow-
ing the mouse to recover. For nerve cut experiments, a 1 mm
section of the nerve was removed to ensure complete transec-
tion. Post-operative mice were maintained in standard animal
house conditions. The individual performing the surgery
remained blind to the genotype of the mice, as were the indi-
viduals who performed all subsequent analyses, ensuring that
operator bias could not adversely influence the experiments.
Electron microscopy
A 5 mm section of the peripheral nerve distal to the injury site
was dissected out in 0.1 M EM-grade phosphate buffer and
immediately fixed in 0.1 M phosphate buffer containing 4%
paraformaldehyde/2.5% glutaraldehyde at 48C. Nerves were
post-fixed in 1% osmium tetroxide overnight. Following dehy-
dration through an ascending series of ethanol solutions and
propylene oxide, nerves were embedded in Durcupan resin.
Ultrathin sections (60 nm) were cut and collected on
formvar-coated grids (Agar Scientific, UK), stained with
uranyl acetate and lead citrate and then quantitatively assessed
in a Philips CM12 transmission electron microscope equipped
with a Gatan camera. Using Adobe Photoshop, individual
images were reconstructed to form entire nerve cross-sections.
For regeneration experiments, higher power images were
taken to allow assessment of large and small myelinated and
unmyelinated axon profiles. All analysis was performed
without the operator knowing the genetic status of the
material.
Immunohistochemical analysis of NMJs
Mice were sacrificed by inhalation of isofluorane (2% in 1:1
N2O/O2). The levator auris longus (LAL; from the dorsal/ pos-
terior surface of the neck) (65), transversus abdominis (from
the anterolateral abdominal wall) (66), first to third deep lumb-
ricals (from the plantar surface of the hind paw) (67) and/or
flexor digitorum brevis (FDB; from the plantar surface of
the hind paw) (67) muscles were dissected in oxygenated
mammalian physiological saline (mM: NaCl 120, KCl 5,
CaCl2 2, MgCl2 1, NaH2PO4 0.4, NaHCO3 23.8, D-glucose
5.6). Muscles were fixed in 0.1 M PBS containing 4% parafor-
maldehyde (Electron Microscopy Science) for 30 min.
Muscles were exposed to a-bungarotoxin (a-BTX) conjugated
to tetramethyl-rhodamine isocyanate (TRITC)-a-BTX; 5mg/
ml, Molecular Probes) for 30 min to label post-synaptic
Table 3. iTRAQ identification of proteins with .20% increased expression and peptide count .1 in regenerating sciatic nerve from ApoE4 mice compared with
ApoE3 mice
Protein name Accession
number
Protein
MW
Protein
PI
Peptide
count
Total ion score, CI
percentage
Best ion
score
Average ratio
(E4/E3)
Standard
deviation (E4/E3)
Haptoglobin precursor 8850219 42455.7 5.9 7 100.00 67.94 3.33 0.12
Orosomucoid 1 15215270 26393.8 5.4 5 100.00 58.65 1.90 0.15
PK-120 precursor 2739028 112522.4 6.1 2 100.00 52.16 1.87 0.01
Haemopexin precursor 160358829 55053.3 7.9 15 100.00 95.47 1.51 0.12
Calpain small subunit 19705421 24752.3 5.1 3 100.00 41.83 1.42 0.13
Unnamed protein product 26345578 19080.7 10.5 3 100.00 67.62 1.41 0.17
Laminin B1 subunit 1 114326497 221889.2 4.9 13 100.00 77.25 1.39 0.13
Fibrinogen, alpha polypeptide, isoform
CRA_b
148683477 68946.6 7.0 6 100.00 64.58 1.38 0.09
Fibrinogen, gamma polypeptide 148683478 55480.4 5.4 6 100.00 84.66 1.38 0.09
CD10 neutral endopeptidase 24.11 192459 93776.9 5.7 2 100.00 52.20 1.37 0.23
Fibrinogen beta chain precursor 33859809 60169.0 6.7 12 100.00 78.56 1.35 0.12
C4 complement protein 50242 137077.1 6.5 2 100.00 47.28 1.34 0.13
2′,3′-cyclic nucleotide 3′
phosphodiesterase isoform 2
226423907 53755.9 9.1 24 100.00 122.44 1.33 0.13
Aspartyl-tRNA synthetase isoform 1 211065507 61980.2 6.1 2 100.00 63.91 1.33 0.03
Predicted: similar to major urinary
protein 1
149252557 28801.5 5.1 4 100.00 85.86 1.32 0.08
Predicted: hypothetical protein
isoform 2
82886943 18543.3 10.3 3 100.00 58.44 1.31 0.12
Hypoxanthine-guanine
phosphoribosyltransferase
2499938 26555.9 5.7 3 100.00 48.91 1.30 0.08
Neural cell adhesion molecule 1
isoform 1
124517689 101275.8 4.8 3 100.00 46.03 1.29 0.13
Glutamine synthetase 31982332 45842.4 6.6 2 100.00 67.62 1.28 0.05
Nucleoside phosphorylase 7305395 34057.1 5.8 3 100.00 67.49 1.28 0.06
Auh protein 20072952 36020.8 9.6 2 100.00 56.44 1.27 0.04
Preprocomplement component C3 309122 205041.7 6.4 6 100.00 56.08 1.27 0.15
Microtubule-associated protein 6
isoform 1
113204613 107716.5 9.5 5 100.00 70.91 1.27 0.10
Nidogen 1 precursor 171543883 143072.8 5.2 23 100.00 76.48 1.27 0.10
Fbxo2 protein 20072543 34278.6 4.3 6 100.00 82.62 1.27 0.17
Laminin, alpha 2 117647249 376116.8 5.8 26 100.00 107.74 1.26 0.15
Breast carcinoma amplified sequence 1 123233481 58733.9 6.2 4 100.00 83.08 1.26 0.09
Solute carrier family 44, member 2 22779895 86584.2 9.1 2 100.00 66.29 1.25 0.15
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Table 4. iTRAQ identification of proteins with .20% decreased expression and peptide count .1 in regenerating sciatic nerve from ApoE4 mice compared with
ApoE3 mice
Protein name Accession
number
Protein
MW
Protein
PI
Peptide
count
Total ion score,
CI percentage
Best ion
score
Average
ratio
(E4/E3)
Standard
deviation
(E4/E3)
Myosin, light polypeptide 3, isoform CRA_a 148677054 27359.4 5.0 5 100.00 54.09 0.38 1.11
Troponin T 2340048 34082.0 9.4 4 100.00 78.26 0.39 0.50
Myozenin 1 10946924 34319.7 8.6 3 100.00 58.73 0.41 0.23
Myosin-binding protein C 81910387 143381.3 6.0 10 100.00 100.37 0.41 0.71
Myosin light chain, phosphorylatable, fast skeletal
muscle
7949078 21485.1 4.8 11 100.00 99.81 0.42 0.94
Myomesin 2 170763465 179757.5 5.6 11 100.00 72.44 0.42 0.63
Calsequestrin 1 127798794 49034.3 3.9 3 100.00 83.23 0.43 0.28
Troponin C 6678371 19609.3 4.1 4 100.00 106.88 0.43 0.27
Fast skeletal myosin alkali light chain 1 isoform 1f 29789016 23699.5 5.0 14 100.00 97.84 0.43 0.82
Troponin I, skeletal, fast 2 123242973 25972.9 9.1 3 100.00 65.23 0.46 0.60
LIM domain binding 3 isoform f 84872217 33857.8 9.2 2 100.00 93.78 0.47 0.55
Muscle creatine kinase 6671762 48101.2 6.6 14 100.00 101.99 0.47 0.56
Myomesin 1 isoform 2 145279198 194032.5 6.0 7 100.00 81.84 0.48 0.54
Actinin alpha 3 7304855 110400.7 5.3 34 100.00 112.37 0.49 0.69
Nebulin 123857937 157734.8 8.8 2 100.00 45.87 0.51 0.63
Titin 123232572 3312853.3 6.2 2 100.00 37.84 0.53 0.25
Igh protein 62028521 56919.8 7.5 3 100.00 71.06 0.54 0.34
Alpha cardiac myosin heavy chain 191618 253883.5 5.6 18 100.00 91.72 0.55 0.25
Myh7 protein 187956918 252607.1 5.6 20 100.00 91.72 0.56 0.26
Myosin, heavy polypeptide 4, skeletal muscle 67189167 254149.5 5.6 86 100.00 127.38 0.56 0.38
LIM domain binding 3 isoform b 84872213 76092.4 8.3 3 100.00 70.38 0.56 0.10
Calcium/calmodulin-dependent protein kinase II
alpha isoform 1
6753250 24580.7 6.5 1 99.85 50.17 0.56 0.02
Myosin, heavy polypeptide 8, skeletal muscle,
perinatal
71143152 253848.8 5.7 46 100.00 106.43 0.56 0.41
Myosin heavy chain IIa 205830428 254268.0 5.6 58 100.00 123.29 0.56 0.38
Myosin, heavy polypeptide 8, skeletal muscle,
perinatal
187956525 253835.8 5.7 47 100.00 106.43 0.57 0.40
Alpha-tropomyosin 157787199 38470.8 4.7 14 100.00 105.62 0.58 0.35
Myosin, heavy polypeptide 1, skeletal muscle,
adult
82524274 254200.7 5.6 71 100.00 127.38 0.58 0.38
Ig H-C allotype gamma2b 223428 40724.8 7.2 2 100.00 90.21 0.59 0.26
Sarcalumenin, isoform CRA_a 148664814 59761.7 6.2 4 100.00 60.15 0.60 0.36
mCG18455 148678485 256334.6 5.5 22 100.00 84.80 0.60 0.39
Tropomyosin 1, alpha, isoform CRA_b 148694194 37823.3 4.7 12 100.00 105.62 0.60 0.39
Predicted: similar to tropomyosin 2 (beta) isoform
2 isoform 15
73971296 38348.4 4.6 17 100.00 86.54 0.61 0.30
Adenylate kinase 1 10946936 26311.9 5.7 5 100.00 77.64 0.63 0.25
Tropomyosin 1, alpha isoform i 78000203 32304.2 4.7 11 100.00 105.62 0.63 0.44
Muscle glycogen phosphorylase 6755256 104509.5 6.7 18 100.00 93.56 0.63 0.32
Myoglobin 21359820 20131.1 7.1 10 100.00 143.49 0.64 0.43
RIKEN cDNA 8030451F13, isoform CRA_c 148689541 142202.0 5.7 4 100.00 52.26 0.64 0.50
Enolase 3, beta muscle, isoform CRA_a 148680653 54402.9 6.8 15 100.00 112.63 0.64 0.60
Actin, alpha 1, skeletal muscle 4501881 45181.8 5.2 12 100.00 91.76 0.65 0.46
mCG2006, isoform CRA_a 148680420 187536.8 6.3 2 100.00 60.73 0.65 0.06
Actinin alpha 2 58476244 111806.5 5.3 20 100.00 112.37 0.65 0.39
ATPase, Ca++ transporting, ubiquitous isoform a 254039658 116671.4 5.5 2 100.00 48.16 0.66 0.09
Alpha actin 1 proprotein 4885049 45033.8 5.2 12 100.00 91.76 0.66 0.45
Alpha 2 actin 4501883 45185.8 5.2 12 100.00 91.76 0.66 0.48
Methylthioadenosine phosphorylase, isoform
CRA_b
148699009 36228.5 6.5 2 100.00 43.65 0.67 0.19
Actinin alpha 2 157951643 112009.7 5.3 23 100.00 112.37 0.67 0.34
Myosin 1945080 253502.8 5.4 17 100.00 83.10 0.67 0.39
Heat shock protein, alpha-crystallin-related, B6 59958370 18132.5 5.6 3 100.00 54.71 0.67 0.17
Sarcomeric mitochondrial creatine kinase
precursor
38259206 51557.9 8.6 2 100.00 46.62 0.69 0.37
Adenylosuccinate synthase like 1 6671519 54920.1 8.6 2 100.00 81.76 0.69 0.07
Growth factor receptor bound protein 2 6680083 27765.1 5.7 2 100.00 45.66 0.69 0.41
ATPase, Ca++ transporting, cardiac muscle, fast
twitch 1
148685412 116243.4 5.3 12 100.00 114.25 0.70 0.14
PDZ and LIM domain protein 3 7948997 36807.6 8.1 3 100.00 68.49 0.70 0.13
mCG147612, isoform CRA_b 148686595 58853.2 5.8 4 100.00 49.09 0.70 0.24
h1-calponin alpha 1069994 36759.9 8.8 4 100.00 68.12 0.72 0.23
Continued
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acetylcholine receptors. Muscles were then immunohisto-
chemically processed to allow visualization of pre-synaptic
motor nerve terminals, as described previously (68). Briefly,
muscles were blocked in 4% bovine serum albumin and
1.5% Triton X-100 in 0.1 M PBS for 30 min before incubation
in primary antibodies directed against 145 kDa neurofilament
proteins (1:250 dilution; Millipore) overnight. After washing
for 2 h in 0.1 M PBS, muscles were incubated for 4 h in a
1:30 dilution of swine anti-rabbit secondary antibody conju-
gated to the fluorescent label FITC (Dako). Muscles were
then whole-mounted in Mowoilw (Calbiochem) on glass
slides and cover-slipped for subsequent imaging.
Microscopy
Fluorescently labelled muscle preparations were viewed using
either a standard epi-fluorescence microscope equipped with a
chilled CCD camera (40× objective; 0.8 NA; Nikon IX71
microscope; Hammamatsu C4742–95) or a laser scanning
confocal microscope (63× objective; 1.4 NA; Zeiss
LSM710). TRITC-a-BTX-labelled preparations were imaged
using 543 nm excitation and 590 nm emission optics, and
FITC-labelled preparations utilized 488 nm excitation and
520 nm emission optics. For confocal microscopy, 488
and 543 nm laser lines were used for excitation, and confocal
Z-series were merged using ImageJ software. All images were
then assembled for analysis, using Adobe Photoshop. A
minimum of 80 NMJs, selected at random, were assessed in
each muscle preparation. Muscles where antibody staining
was too faint to quantify due to poor antibody penetration
and muscles with damage to either the muscle fibres or
nerves from dissection were excluded from further analysis.
All analyses were performed without the operator knowing
the genetic status of the material. For occupancy counts, end-
plates were categorized as either vacant (no neurofilament
overlying the endplate), partially occupied (neurofilament par-
tially overlying the endplate) or fully occupied (neurofilament
entirely overlying the endplate). For the assessment of devel-
opmental synapse elimination, fully occupied endplates were
further subdivided on the basis of the number of axonal
inputs contacting the endplate. For neuromuscular
re-innervation experiments, an individual endplate was
required to be fully occupied by an incoming single axon
profile to be considered re-innervated.
Electrophysiology
Freshly dissected FDB muscles were used to obtain intracellu-
lar recordings (69) of evoked EPPs and spontaneous mEPPs.
Isolated muscles were pinned out in a Sylgard (VWR Inter-
national, Poole, UK)-lined bath and perfused with oxygenated
mammalian physiological saline (see above). Muscle contrac-
tions were reduced or eliminated by bathing the muscles in
2.5 mM m-conotoxin GIIIB (Scientific Marketing Associates,
Table 4. Continued
Protein name Accession
number
Protein
MW
Protein
PI
Peptide
count
Total ion score,
CI percentage
Best ion
score
Average
ratio
(E4/E3)
Standard
deviation
(E4/E3)
Myosin, light polypeptide kinase 55930915 237267.2 6.0 2 100.00 46.40 0.72 0.24
Parvalbumin 31980767 14372.8 5.0 5 100.00 88.79 0.72 0.41
UDP-glucose ceramide glucosyltransferase-like 1 45946485 190971.6 5.4 2 100.00 43.57 0.72 0.02
Predicted: similar to tropomyosin 3 isoform 1 149751320 32645.1 4.8 10 100.00 80.10 0.74 0.37
Carboxylesterase 192854 65222.7 5.0 8 100.00 84.01 0.74 0.09
Phosphoglycerate mutase 2 9256624 31972.9 8.7 8 100.00 89.17 0.74 0.54
Skeletal muscle LIM protein 2880031 38678.1 8.8 2 100.00 78.07 0.75 0.23
RIKEN cDNA 1810020D17, isoform CRA_c 148684357 17880.5 7.8 2 100.00 44.25 0.75 0.09
Aldolase A, fructose-bisphosphate 42490830 43401.8 8.5 11 100.00 91.23 0.75 0.17
Albumin precursor 163310765 77836.5 5.8 36 100.00 121.79 0.77 0.26
SH3P9 1438563 53597.8 5.1 4 100.00 62.83 0.77 0.12
Creatine kinase, mitochondrial 1, ubiquitous,
isoform CRA_c
148696104 50564.3 8.5 2 100.00 59.05 0.77 0.04
Milk fat globule-EGF factor 8 protein isoform 2 113865977 50796.5 6.7 5 100.00 83.22 0.77 0.20
ATPase, Ca++ transporting, slow twitch 2
isoform a
158635979 124907.5 5.2 5 100.00 68.51 0.78 0.32
Proteasome alpha 6 subunit 6755198 30608.7 6.3 2 100.00 75.58 0.78 0.18
Liver glycogen phosphorylase 18875342 107417.7 6.6 5 100.00 58.28 0.78 0.28
Solute carrier family 4 (anion exchanger),
member 1
6755560 108215.2 5.4 2 100.00 50.97 0.78 0.06
Coagulation factor II 123227411 76215.8 6.0 4 100.00 61.55 0.79 0.08
TRIO and F-actin binding protein isoform 3 88501749 234306.2 8.4 2 100.00 36.79 0.79 0.04
Ig gamma-3 chain C region 121044 47963.7 6.7 3 100.00 46.58 0.79 0.01
Filamin, alpha 125347376 305825.3 5.7 29 100.00 89.05 0.79 0.20
Glyceraldehyde-3-phosphate-dehydrogenase
isoform 1
149272161 40122.8 7.1 3 100.00 86.97 0.79 0.05
Phosphoglucomutase 2 55824767 66748.2 6.0 10 100.00 75.31 0.80 0.23
C-1-tetrahydrofolate synthase, cytoplasmic 34921990 110015.8 6.9 2 100.00 40.34 0.80 0.31
Alpha actinin 1a 82659196 111086.8 5.3 32 100.00 112.37 0.80 0.33
Acyl-CoA thioesterase 2 39992610 52675.7 7.2 2 100.00 53.32 0.80 0.22
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UK) for 30–45 min. Thirty muscle fibres per muscle were
sampled using glass microelectrodes filled with 4 M potassium
acetate (impedance 30–40 MV), according to standard tech-
niques. Spontaneous and evoked EPPs were recorded using
Axoclamp 2B amplifiers (Axon Instruments) and stored and
analysed on a PC using WinWCP v3.9.5 software (developed
and distributed by Dr John Dempster, Strathclyde University).
Average frequency of spontaneous MEPPs was obtained from
continuous records of 10–60 s duration. The quantal content
of EPPs was determined from measurements of peak EPP
amplitude in trains evoked at stimulation frequencies of
0.5–2 Hz, using the variance method and applying the McLa-
chlan–Martin formula for correction of non-linear summation
of EPPs (70), with the modifier f ¼ 3D0.3.
iTRAQ proteomics
Unlesioned tibial nerves from nine apoE3 and nine apoE4
mice were pooled into three groups for each genotype, and
underwent iTRAQ proteomic analysis. This was repeated
with nine nerves from each genotype 3 weeks after tibial
nerve crush. Nerves were extracted in buffer containing 6 M
urea, 2 M thiourea, 2% CHAPS and 0.5% SDS in dH2O. The
proteins were precipitated in six volumes of ice-cold acetone
overnight at 2208C. Acetone precipitates were pelleted by
centrifugation at 13 000g for 10 min at 48C and the super-
natant was carefully removed and discarded. The pellets
were allowed to air-dry, followed by resuspension in 6 M
urea in 50 mM TEAB. The protein concentration in each
group was determined using a Bradford assay.
Reduction, alkylation and digestion steps were performed
using the reagents and according to the recommendations in
the iTRAQ labelling kit (Applied Biosystems). The extracts
were diluted with 50 mM TEAB so that the urea concentration
was ,1 M, before the addition of trypsin and overnight incu-
bation at 378C. The digests were then dried down in a
vacuum centrifuge and iTRAQ labelling was carried out
according to the instructions in the iTRAQ labelling kit. The
iTRAQ tags were assigned to samples as follows:
115-ApoE3 and 117-ApoE4. Each tag was incubated with
85 mg of protein (as determined by a Bradford protein assay).
iTRAQ-labelled peptides were pooled and made up to a
total volume of 2.4 ml in strong cation-exchange (SCX)
buffer A [10 mM phosphate, pH 3, in 20% acetonitrile
(Romil, UK)]. The pooled peptides (2.4 ml) were then separ-
ated by SCX chromatography using a polysulfoethyl A
column, 300 A˚, 5 mM (PolyLC)) at a flow rate of 400 ml/
min. Following sample injection, the column was washed
with SCX buffer A until the baseline returned. The gradient
was run as follows: 0–50% SCX buffer B (10 mM phosphate,
1 M NaCl, pH3, in 20% acetonitrile) over 25 min followed by a
ramp up from 50 to 100% SCX buffer B over 5 min. The
column was then washed in 100% SCX buffer B for 5 min
before equilibrating for 10 min with SCX buffer
A. Fractions were collected (400 ml) during the elution
period and dried down completely in a vacuum centrifuge.
The iTRAQ tryptic peptide fractions were each resuspended
in 30 ml of RP buffer A (2% acetonitrile, 0.05% TFA in water;
Sigma Chromasolv plus). Prior to mass spectrometry analysis,
fractions were first separated by liquid chromatography
(Dionex Ultimate 3000) on a Pepmap C18 column,
200 mm × 15 cm (LC Packings) at a flow rate of 3 ml/min.
Fractions were injected by full-loop injection (20 ml) and the
order of loading was randomized to minimize effects from car-
ryover. The eluants used were (A) 0.05% TFA in 2% aceto-
nitrile in water and (B) 0.05% TFA in 90% acetonitrile in
water. The gradient was run as follows: 10 min isocratic
pre-run at 100% A, followed by a linear gradient from 0 to
30% B over 100 min, followed by another linear gradient
from 30 to 60% over 35 min. The column was then washed
in 100% B for a further 10 min, before a final equilibration
step in 100% A for 10 min. During the elution gradient, the
sample was spotted at 10 s intervals using a Probot (LC Pack-
ings) with a-cyano-4-hydroxycinnamic acid at 3 mg/ml (70%
MeCN, 0.1% TFA) at a flow rate of 1.2 ml/min.
Both MS and MS/MS analyses were performed on the frac-
tionated peptides using an Applied Biosystems 4800 MALDI
TOF/TOF mass spectrometer. The mass spectrometer was
operated under the control of 4000 Series Explorer v3.5.2 soft-
ware (Applied Biosystems). A total of 1000 shots per MS
spectrum (no-stop conditions) and 2500 shots per MS/MS
spectrum (no-stop conditions) were acquired. The following
MS/MS acquisition settings were used: 2 kV operating mode
with CID on and precursor mass window resolution set to
300.00 (FWHM). Peak lists of MS and MS/MS spectra were
generated using 4000 Series Explorer v3.5.2 software and
the following parameters were used after selective labelling
of monoisotopic mass peaks: MS peak lists: S/N threshold
10, Savitzky Golay smoothing [three points across peak
(FWHM)], no baseline correction; MS/MS peak lists: S/N
threshold 14, Savitzky Golay smoothing [seven points across
peak (FWHM)].
An automated database search was run using GPS Explorer
v3.6 (Applied Biosystems). MASCOT was used as the search
engine to search the NCBI non-redundant database (version
10/11/2009), using the following search parameters: precursor
ion mass tolerance of 100 p.p.m., MS/MS fragment ion mass
tolerance of 0.3 Da and iTRAQ fragment ion mass tolerance
of 0.2 Da. The enzyme was specified as trypsin with one
missed cleavage permitted, oxidation of methionine residues
were allowed as variable modifications and N-terminal
(iTRAQ), lysine (iTRAQ) and MMTS modification of
cysteine residues were set as fixed modifications and the tax-
onomy was selected as Mus. The identification criterion was
at least two unique peptides by MS/MS with the most stringent
search settings in order to yield the most reliable data for
iTRAQ quantification (peptide rank 1 and total ion score con-
fidence intervals of at least 95%).
Peptides were reported as identified iTRAQ peptides only if
they met the following criteria: iTRAQ ratio of greater than 0,
all N-terminal and lysine residues were labelled and did not
include tyrosine_iTRAQ modification. Quantification of the
iTRAQ peptides was performed by applying the following
formula: corrected cluster area of fragment/corrected cluster
area of reference [i.e. 117 (ApoE4)/115 (ApoE3)]. Following
correction using kit-specific iTRAQ correction factors,
iTRAQ ratios were normalized to the median ratio, using the
following formula: iTRAQ ratio ¼ ratio/median iTRAQ ratio
of all found pairs. Both correction and normalization were per-
formed using GPS Explorer software v3.6.
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To obtain further insights into cellular pathways and protein
interaction networks modified as a result of apoE genotype,
the IPA application (Ingenuity Systems) was used. IPA dyna-
mically generates network of gene, protein, small molecule,
drug and disease associations on the basis of ‘hand-curated’
data held in a proprietary database. Changes in specific
protein interaction networks were identified on the basis of
the number and percentage of candidate proteins contributing
to the entire network.
Quantitative fluorescent (Li-COR) western blots
Total protein was isolated from distal nerve stumps and quan-
titative western blots were performed as described previously
(71–73). Briefly, protein was separated by SDS/polyacryl-
amide gel electrophoresis on 4–20% pre-cast NuPage
4–12% Bis Tris gradient gels (Invitrogen) and then transferred
to PVDF membrane overnight. The membranes were blocked
using Odyssey blocking buffer (Li-COR) and incubated with
primary antibodies as per manufacturers’ instructions (apoE,
Millipore; tubulin, Abcam). Odyssey secondary antibodies
were added according to manufacturer’s instructions (donkey
anti-goat IRDye 680 and goat anti-rabbit IRDye 680). Blots
were imaged using an Odyssey Infrared Imaging System
(Li-COR Biosciences).
Statistical analysis
All data were collected into Microsoft Excel spreadsheets and
analysed using GraphPad Prism software. All bar charts shown
are mean+SEM. Statistical significance was considered to be
P, 0.05 for all analyses. Individual statistical tests used are
detailed in figure legends.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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